The topical administration of 7H-dibenzo [c,g]carbazole (7H-DBC) at very low but repeated doses causes genotoxic effects such as DNA adduct formation and produces hepatocellular apoptosis in mouse liver. The purpose of this work was to investigate the alterations in gene expression and protein levels of biomarkers associated with the p53 pathway in mouse liver after exposure to cumulative low doses of 7H-DBC by skin paint applications. The compound was administered topically at the dose of 13.35 µg per animal every 2 days to give either 6, 8, 10, or 12 applications. Animals were sacrificed 48 hours after the different treatments. The apoptotic index increased with the number of applications, with a major proportion of apoptotic cells in the periportal areas. A significant increase of Bax mRNA and protein expression was observed after the 8th application whereas the expression of mRNA levels of Fas and p53 did not show significant differences between treated and control animals. Nuclear staining of p53 was detected in hepatocyte nuclei showing the activation of this protein. Later in the apoptosis process we observed the up-regulation of TGF-β1 in parenchymal cells. In addition to the induction of the p53 apoptosis pathway in vivo by 7H-DBC, we have observed molecular changes related to cell proliferation such as the overexpression of the antiapoptotic gene Bcl-2.
INTRODUCTION
The heterocyclic 1 aromatic compound 7H-dibenzo[c,g]carbazole (7H-DBC) is an important environmental carcinogen, occurring in complex mixtures derived from the incomplete combustion of organic materials (Washawsky et al., 1996) . This aromatic hydrocarbon is widely found in various sources such as tobacco smoke and coal, and induces both local and distant tumors in mice, having greater effects in female than in male animals (Périn et al., 1984; Valéro et al., 1985; Dorchies et al., 2001) . The genotoxic activity of this compound has been established using different in vitro approaches (Périn et al., 1988) and 15 separate DNA adducts induced by 7H-DBC have been detected in mouse liver (Périn-Roussel et al., 1995) . In addition, Tombolan and colleagues (Tombolan et al., 1999a (Tombolan et al., , 1999b ) demonstrated this mutagenic activity in vivo using the lacZ transgenic mouse assay. In previous work (Dorchies et al., 2001) we have described the kinetics of adduct formation and cell proliferation in liver from female mice treated with low cumulative doses of 7H-DBC. The protocol used in that work reproduced closely the risks for humans exposed to very low but regular doses of this molecule or similar compounds. We observed the formation of DNA adducts in the liver from the second application with a peak of proliferation at the eighth application. Conversely, histological changes such as hepatocellular apoptosis, were not observed until the eighth application. We have chosen this protocol to study the early molecular events occurring in the liver induced by the DNA adduct forming 7H-DBC through the analysis of the expression of apoptosis related genes.
Exposure of cells to a variety of DNA damaging agents leads to a rise in p53 protein which in its role as the "Guardian of genome" (Lane, 1992) arrests the cell cycle to allow repair, or if this is not possible, promotes cell deletion by apoptosis through the transcriptional activation of genes (Levine, 1997) . The induction of the p53 response by compounds which induce DNA adducts such as benzo(a)pyrene (Bjerlogrlic et al., 1994; Rämet et al., 1995) has been described. Recently, O'Brien et al. have shown an increase of p53 protein levels followed by apoptosis and cell death induced by DBC-DNA adducts in a human hepatoma cell line. The p53-mediated stress response included the stabilization of the p53 protein, its translocation to the nucleus, and the activation and suppression of p53-responsive genes. p53 has also been shown to up-regulate pro-apoptotic genes such as Bax in vivo (Yin et al., 1997) and in vitro (Mitry et al., 1997) and to suppress anti-apoptotic genes such as Bcl-2, thus altering the relative quantities of Bax to Bcl-2 and shifting the balance towards apoptosis (Miyashita et al., 1994) . In addition to the relative ratios of anti-apoptotic and pro-apoptotic Bcl-2 family proteins, their location in the cell play an essential role in apoptosis. For example, about half the Bax protein found in cells typically resides in the cytosol until an apoptotic signal is delivered which causes its insertion into mitochondrial membranes (Wolter et al., 1997) In addition to the transcriptional control by p53 of several Bcl-2 family members, p53 can also induce the expression of other proteins involved in apoptosis such as the membrane receptor Fas (CD95/APO1) (Owen-Schaub et al., 1995; Muller et al., 1997) . Loss of the protective function of p53 leads to an inadequate response to DNA damaging agents, resulting in genomic instability of the cell. These alterations would allow for subsequent tumour expansion and offer a selective advantage for cells containing p53 mutations (Vogelstein and Kinzler, 1992) . We report here the activation of the p53 pathway in the early stages of hepatotoxicity induced by 7H-DBC in mouse liver, as shown by the nuclear localization of p53 in hepatocytes of treated animals and the induction of p53 responsive genes.
In addition to the analysis of the p53 pathway as a response to genotoxic damage, we have studied if other apoptotic related proteins were involved in the damage induced by 7H-DBC. It is known that Transforming Growth Factor β-1 (TGF-β1) plays an important role in hepatic pathophysiology and it is a potent inhibitor of hepatocyte growth by the induction of apoptosis both in vivo and in vitro (Oberhammer et al., 1992) . The biological effects of TGF-β1 on cell growth and differentiation are complex and vary according to cell type. It has been proposed that TGF-β1 may function in vivo as a negative paracrine effector of hepatocyte proliferation (Braun et al., 1988; Russell et al., 1988) and that this factor may also have an autocrine role in the development of carcinoma (Sporn and Roberts, 1985) . The escape of tumour cells from TGF-β1 mediated cell death and the ability of TGF-β1 to suppress the immune response, to promote angiogenesis and to enhance extracellular matrix deposition implicate this factor as a key modulator in epithelial carcinogenesis (Roberts et al., 1988) . Increases in TGF-β1 expression in the liver have been described during carcinogenesis , and TGF-β1 spontaneously has also been shown to promote transformation of rat liver epithelial cells (Zhang et al., 1994) . In the present work we have also studied the expression of this factor.
MATERIALS AND METHODS

Chemicals and Reagents
H-DBC was obtained from the Institut Curie-Recherche (Orsay, France) and synthesised by Perin and colleagues (1984) . The TdT-FragEL DNA fragmentation detection kit was purchased from Oncogene Research Products. The RAN extraction kit RNeasy was supplied by Qiagen and the First strand cDNA synthesis kit from Pharmacia Biotech. Platinum Taq DNA polymerase, dNTPs, 100bp DNA ladder and agarose for electrophoresis were purchased from GibcoBRL. Antibodies were obtained from different suppliers: a mouse monoclonal (clon 13) anti-human Fas IgG1 from Transduction Laboratories); a rabbit (sc-146) polyclonal anti human TGF-β1 antibody, a mouse monoclonal IgG2b antibody (B-9) anti-murine Bax, and a goat polyclonal (sc-6243-G) antibody anti-human p53 from Santa Cruz Biotechnology, Inc.; a biotinylated swine anti-rabbit immunoglobulin, a biotinylated rabbit anti-mouse antibody, and a peroxidaseconjugated rabbit anti-goat immunoglobulin from Dako (Dako). The ABComplex/HRP was also supplied by Dako.
Animals and Experimental Procedures
Seven-to 8-week-old DBA/2 female mice (Charles River, Saint Aubin Lès Elbeuf, France) were maintained in specificpathogen-free housing, under controlled temperature, humidity and lighting conditions and receiving a standard diet (UAR A04 c10 pellets, France) and fresh drinking water ad libitum. They were allowed to acclimate for at least 1 week before the study. All animal care and handling procedures met the requirements of the applicable NIH guidelines.
Four groups of 5 animals were treated in the interscapular region by topical administration of 0.05 µmol (13.35 µg) of 7H-DBC in 100 µl acetone on shaved skin. The product was applied every two days to give either 6, 8, 10, or 12 applications. In order to detect the early molecular changes induced by this compound, each group was sacrificed 48 hours after the last application. A control group constituted of 5 animals was treated topically with 12 applications of acetone and sacrificed under the same experimental conditions. All animals were euthanatized by exsanguination after isofluorane (Forene, Abbott, France) anaesthesia. The livers were sampled and small slices (5-mm thick) from different liver lobes (left lateral lobe, right lateral lobe, left and right portions of median lobe) were fixed in 10% buffered formalin solution for less than 30 hours and subsequently embedded in paraffin wax for routine light microscopy and immunohistochemistry. A small piece of liver from the left lateral lobe of each animal in all groups was snap frozen in liquid nitrogen and stored at −70 • C for mRNA analysis.
Light Microscopy and Apoptosis Detection
Hepatocyte apoptosis in liver sections was quantified using a variation of the TUNEL method (Tdt-mediated dUTP nick end labeling), with the TdT-FragEL DNA fragmentation detection kit from Oncogene Research Products. The manufacturers' recommendations were followed and after cell labelling, slides were counterstained by immersion in Mayer's Haematoxylin. Morphological criteria were used to differentiate necrotic from apoptotic cells. Apoptotic cells were identified by means of the association of DNA fragmentation labeling with apoptotic cell morphology such as membrane blebbing and nuclear condensation. The percentage of apoptotic cells (Apoptotic Index) was evaluated for each animal from the different liver lobes and functional regions (centrilobular and periportal). Individual values were obtained by hepatocyte counting in 4 centrilobular and 2 periportal fields in each liver lobe (magnification of ×25). The effect of each factor (number of applications, lobe and area) in the Apoptotic Index was evaluated by means of a multivariate analysis of variance (MANOVA) test. Appropriate post hoc tests were subsequently performed to elucidate any differences found. p < 0.05 was considered statistically significant.
RT-Competitive PCR
The levels of mRNA of the apoptosis related genes p53, Bax, Bcl-2, Fas (CD-95/APO-1), and TGF-β1 were analysed by RT-Competitive PCR using DNA competitors. Expression levels of two housekeeping genes (GAPDH and β-actin) were also analysed using this method.
Total RNA was extracted from approximately 50 mg of liver tissue using the mini RNeasy kit from Qiagen according to the manufacturer instructions. Complementary DNA (cDNA) was synthesised from 5 µg of each RNA preparation using random hexamer primers with the First strand cDNA synthesis kit from Pharmacia Biotech.
A PCR-MIMIC strategy was employed to construct PCR-fragments for competitive and semiquantitative reverse transcription-PCR-assays (RT-competitive PCR). This method is based on co-amplification of an internal standard and the target cDNA sequence with one set of primers (Wang et al., 1989; Gilliland et al., 1990) . Forward and reverse primers were designed based on Genbank sequences for specific amplification of the target genes (see Table 1 for primer sequences). The internal standards were prepared using a nonhomologous fragment of DNA (PCR MIMIC) of 228 bp ligated to the specific primers used to amplify the target genes. As a first step, the MIMIC was obtained by PCR from mouse genomic DNA using the forward primer: 5 tgtccatcttgtgggcct 3 and the reverse primer: 5 cttctgcaggtggaagagc 3 . The amplicon obtained was reamplified using composite primers containing the sequences of target genes as specific primers to their 5 -ends. To perform semiquantitative PCRs, different quantities of cDNA template were used according to the basal expression level of each marker and a known quantity of PCR MIMICs was added to the different reactions. The quantities of cDNA equivalent to µg of RNA selected for each amplification and the RT-PCR fragment size are shown in Table 1 . PCR was performed in 50 µl reactions using 2.5 units of Platinum Taq DNA Polymerase (GibcoBRL) and the reaction cycles chosen were 30 or 35 according to the initial expression of each specific marker. PCR reactions were then analysed using 2% agarose gel electrophoresis and staining with ethidium bromide. Intensity of target and PCR MIMIC bands were determined using the Gel Doc 2000 apparatus (Biorad) using the Quantity One 4.1 program. As an equal quantity of internal standard was introduced in each PCR reaction, relative expression levels for each marker in each slice were expressed as the ratio between target and PCR mimic intensities. For cDNA synthesis efficiency control, the value obtained for each marker in each animal was normalized with the value obtained for the housekeeping gene GAPDH. Mean expression values of GAPDH, p53, Bcl-2, Bax, and Fas were obtained from data of 5 animals from each group. Due to RNA completion TGF-β1 expression was analyzed in only 1 animal from each group.
As we said above, expression data obtained from the p53, Bax, Bcl-2, and Fas genes were normalized using the expression data obtained for the GAPDH gene. The normalized data of each group were then analyzed using one-way analysis of variance (ANOVA) to determine whether there was a significant difference between groups as a consequence of treatment. A Kruskal-Wallis test was subsequently performed to elucidate any differences found. P < 0.05 was considered statistically significant.
Immunohistochemistry
Staining of the different markers was made using 4-µm thick paraffin sections. Immunohistochemical detection of Fas was performed with a mouse monoclonal (clone 13) anti-human Fas IgG1 (Transduction Laboratories) 1:2,000 dilution. After sequential layering with biotinylated rabbit anti-mouse (Dako) 1:200 dilution as secondary antibody, the ABComplex/HRP (Dako) was applied. Transforming Growth Factor-β 1 (TGF-β1) protein was revealed using a rabbit (sc-146) polyclonal anti-human TGF-β1 antibody (Santa Cruz Biotechnology, Inc.) 1:40 dilution, a biotinylated swine antirabbit immunoglobulin (Dako) 1:100 dilution and final incubation with the ABComplex/HRP (Dako). Prior to incubation with blocking serum, paraffin embedded tissue sections were treated with 1% SDS in PBS for TGF-β1 staining. A microwave antigen unmasking protocol (immersion in 10 mM citrate buffer and treatment for 5 minutes at 750 W, 5 minutes cooling, 1 min at 750 W, 4 minutes at 300 W and 15 minutes cooling) was performed before blocking serum incubation in Bax and p53 immunostaining. A mouse monoclonal IgG2b antibody (B-9) anti-murine Bax (Santa Cruz Biotechnology, Inc.) was applied for Bax protein detection. Afterwards, the specimens were incubated with a biotinylated rabbit anti-mouse antibody (Dako) 1:200 dilution followed by the ABComplex/HRP (Dako). Immunohistochemical localization of p53 protein in mouse liver tissue was detected with a goat polyclonal (sc-6243-G) antibody antihuman p53 (Santa Cruz Biotechnology, Inc.) 1:40 dilution and a peroxidase-conjugated rabbit anti-goat immunoglobulin (Dako) 1:100 dilution. In all cases, antibody dilutions were done in PBS with normal serum 10% and Tween 0.05% and incubation times were 1 hour for blocking serum and primary antibodies and 30 minutes for secondary antibodies. All incubations were done at room temperature and the staining was visualised with diaminobenzidine. The sections were finally counterstained with Mayer's haematoxylin. In the immunohistochemical reactions, a negative control slide was included in which the first antibody was replaced by a similar dilution of normal serum.
RESULTS
Histopathology and Apoptosis Induced by 7H-DBC in Mouse Liver
Histological sections from liver of mice sacrificed 48 hours after the last application of 7H-DBC were examined at each time of sacrifice. We have previously reported the lesions in mouse liver produced by the cutaneous administration of 7H-DBC (Dorchies et al., 2001) . No significant compoundrelated histological changes in the liver of mice were observed until the eight application of 7H-DBC, where a moderate apoptosis and single cell necrosis (presence of unicellular necrosis associated with few inflammatory cells) were observed. In the group that received ten cumulative applications the hepatocytes appeared to be hypertrophied with a microvesicular cytoplasm, and minimal bile duct hyperplasia was noted. This phenomenon was accentuated by the 12th application and was associated with cellular atypia showing cytomegaly and karyomegaly throughout the parenchyma. In this group an accentuation of the bile duct hyperplasia was also observed. Vol. 32, No. 2, 2004 DBC INDUCED APOPTOSIS IN MOUSE LIVER 205 The TUNEL method combined with a morphological analysis was used to identify and quantify apoptotic cells. Positive stained nuclei were observed in all groups. The apoptotic index was calculated for each animal with respect to the liver lobe and functional area. A MANOVA test revealed that the different number of cumulative applications of 7H-DBC and the liver area have a significant impact on the Apoptotic Index, showing a p-value < 0.001 for the number of applications and equal to 0.006 for the area. The effect of these factors was independent as shown by the p-value (0.283) of the combined effect. The mean Apoptotic index increased with the number of applications, and the major proportion of apoptotic cells was detected in the portal areas The MANOVA test did not show any significant differences between lobes, neither as an individual nor as a combined effect with the number of applications and/or the liver area. The LSD test was used to determine differences between groups using the number of applications as the main effect. Significant differences ( p < 0.01) were detected for all possible group pairings except for the group that received 8 and 10 cumulative applications of DBC ( p = 0.719). Table 2 shows the mean value for the Apoptotic Index using the number of cumulative applications and the liver area.
A magnification factor of 25× was used for the hepatocyte counting in 16 centrilobular and 8 periportal areas for each animal. The mean number of hepatocytes in each analyzed area was decreased with the number of applications of 7H-DBC (see Table 2 ). The MANOVA test determined that the number of cumulative applications ( p < 0.001) as well as its combined effect with the liver area ( p < 0.001) induced a significant decrease in hepatocyte number. Significant differences were found between the groups that received different number of 7H-DBC applications. The liver area effect for the group that received 12 applications was highly significant being much lower the number of cells in the centrilobular areas ( p < 0.001).
Early Expression of Apoptosis Related Genes
To determine what genes showed altered expression in the apoptosis induced by 7H-DBC, a battery of known genes related to both the p53 pathway as well as TGF-β1 were analysed by RT-Competitive PCR. Total RNA was extracted from liver of control and treated mice and mRNA levels of Bax, Bcl-2, Fas, and p53 were studied. The housekeeping genes GAPDH and β-actin were also analysed using the same technique. A significant increase in β-actin expression was observed in treated animals (data not shown), conversely, GAPDH expression levels were constant (Figure 1 ). (26) Mean apoptotic index in centrilobular and periportal areas. Apoptosis was detected by a modified TUNEL method. Positive cells were counted in 16 centrilobular and 8 periportal fields (magnification 25×) in 5 animals from control and treated groups. Data are given as means of the percentage of apoptotic cells (A.I.), standard error (S.E.) are in bracket; P: probability for post hoc tests between control and treated groups; Cells: mean number of hepatocytes counted in each field, standard errors (S.E.) are in bracket. FIGURE 1.-Expression of apoptosis related genes: A semiquantitative MIMIC RT-PCR was carried out to determine the differences in p53, Bcl-2, Bax, and Fas mRNA levels in liver from mice treated with 6, 8, 10, and 12 cumulative applications of 7H-DBC. Expression of each biomarker in each animal was normalized with the value obtained for the housekeeping GAPDH in the same animal. The value 1 was given to the mean value of mRNA levels for each marker in the control group. Significant differences ( p < 0.05) between control and treated groups are indicated ( ) as well as the differences obtained in other group pairings.
Although the mRNA for β-actin remains a widely used housekeeping gene internal control, there are circumstances in which β-actin is also regulated. In cancer studies there is often a generalized increase in mRNA production due to heightened cellular metabolism, and certain genes that are often used to gauge alterations in expression, such as the β-actin gene may also be affected (Selvey et al., 2001) . As GAPDH was not changed under the conditions of our study, this gene was chosen as a control of cDNA synthesis and expression levels of target genes were compared to this marker.
The mean of the gene expression levels of control animals was considered as the basal level and the value 1 was assigned for easier interpretation of semiquantitative results. Figure 1 shows the expression levels of p53, Bcl-2, Bax, and Fas compared to the housekeeping gene GAPDH. Relative mRNA expression levels of the tumor supressor gene p53 were similar in control and treated animals. Nevertheless, an overexpression was observed in Fas and Bax both of which are controlled by p53. Fas was slightly up-regulated in the treated groups although a significant increase was not observed (Kruskal-Wallis ANOVA p = 0.0607). Bax, the 206 MARTÍN-BURRIEL ET AL.
TOXICOLOGIC PATHOLOGY pro-apoptotic Bcl-2 family member, was up-regulated in all treated groups. Its expression levels increased from control to 8 applications of 7H-DBC and was similar in the three groups treated with the highest cumulative doses. Significant differences ( p < 0.05) were observed between the control and the groups treated with 8, 10 and 12 cumulative applications of 7H-DBC (Figure 1 ). Using the same methodology, the analysis of the antiapoptotic Bcl-2 marker showed a significant increase in the groups receiving 8, 10, and 12 applications of 7H-DBC. As well as Bax, this marker did not show significant differences between these three groups. Finally, the mRNA expression of TGF-β1 was studied in one animal from each group, an overexpression was detected in the animal that received 12 applications of DBC compared to GAPDH expression. Although a quantitative analysis was not done for this marker, the increase of TGF-β1 in the group that received the greatest number of cumulative applications was confirmed by immunohistochemistry (see next).
Immunohistochemical Analysis
Control animals showed a homogeneously distributed staining for Bax, that was slightly stronger in centrilobular areas in hepatocytes adjacent to the central vein and in some isolated parenchymal cells. After 6 applications, mice showed a similar staining, however apoptotic hepatocytes were identified which presented a more intense staining for this biomarker. Although a quantitative analysis was not done, the surface area and intensity of staining as well as the number of scattered hepatocytes showing an overexpression of Bax appeared to increase after the 8th application, although differences between the groups receiving 8 and 10 applications were not noticeable. In the group of mice treated with the highest cumulative dose the tissue organization was lost, and the amount of stained cells was much higher than in the other groups. Strongly stained hepatocytes showed a discrete staining which may correspond with localization of Bax in the mitochondria during apoptosis (data not shown). Figure 2 shows some representative images from liver sections corresponding to mice treated with different numbers of cumulative applications of 7H-DBC.
With respect to the immunostaining results for the membrane cell death receptor Fas, control animals showed an homogeneous staining slightly stronger in centrilobular areas although in some animals we could also observe this staining in hepatocytes adjacent to portal tracks. The intensity of Fas staining appeared to increase with the treatment in periportal areas although it is very difficult to establish quantitative differences between groups. Only the 12 application group was clearly different from the remaining treated groups. As in the immunohistochemical determination of Bax, we did not observe a precise distribution of Fas overexpression in liver from mice treated with 12 applications of 7H-DBC. Figure 2 shows the staining patterns for control animals as well as for mice treated with different numbers of compound applications.
The staining for p53 in control animals was only detected in some isolated mesenchymal macrophages (Figure 3) . This staining was also present in treated animals. In spite of the fact that p53 was not detected in hepatocytes from control mice, animals treated with 6, 8, and 10 cumulative applications of 7H-DBC showed a slight nuclear staining for p53 in a few hepatocytes, although this staining was hardly detectable and was only observed with higher magnification objective (data not shown). A more intense p53 staining was detected in the nucleus of hepatocytes in the group receiving 12 applications of 7H-DBC. In addition to the nuclear localization, we also observed in the liver from these animals some hepatocytes with a marked p53 cytoplasmic staining. Figure 3 shows the different staining patterns observed in mice treated with the genotoxic compound 7H-DBC.
Finally, TGF-β1 expression was observed in sinusoidal and vascular cells both in control and animals treated with 6, 8, and 10 applications of 7H-DBC. Apoptotic hepatocytes were observed in addition in treated animals which presented a stronger staining for this marker. As for the results obtained with Bax and Fas, the areas of stained hepatocytes were much more extensive in liver from mice treated with 12 applications of 7H-DBC (Figure 3) . DISCUSSION 7H-DBC is described as a genotoxic compound (Périn et al., 1988 ) that forms DNA adducts (Périn-Roussel et al., 1995) and produces tumours in mouse liver (Valéro et al., 1985; Dorchies et al., 2001) . In this work we have analyzed the early damage produced by this compound in mouse liver by means of the quantification of apoptosis and the analysis of apoptosis related genes. We have previously reported the effect of this compound in mouse liver after repeated administration of low doses of DBC (Dorchies et al., 2001) . Although a marked increase of the total adduct level in the liver was observed from the second application of the compound until the thirteenth, in that work we only observed hepatocellular apoptosis after the 8th cumulative application of DBC. It has been proposed that the loss of liver cells with subsequent cell proliferation could be the mechanisms leading to the fixation of DNA adducts into stable mutations (Tombolan et al., 1999a (Tombolan et al., , 1999b . In spite of using the same protocol, we Vol. 32, No. 2, 2004 . 32, No. 2, 2004 DBC INDUCED APOPTOSIS IN MOUSE LIVER 209 observed here the presence of apoptosis as early as the sixth application. The detection of apoptosis at earlier applications was the consequence of using a more sensitive technique (TUNEL) for detecting apoptotic nuclei, and indicated that the critical adduct level from which they induced toxicity could be lower. In our study, large interanimal variations were observed in the apoptotic index of the groups that received a high number of applications of 7H-DBC, and this fact is in agreement with the results of Tombolan et al. (1999a) with respect to the variations of the mutation frequency in liver from mice treated with high doses of 7H-DBC. In accordance with our previous results, the apoptosis index revealed that DBC toxicity increased with the number of applications and was higher in periportal areas. While there were not significant differences in the apoptosis index from groups that received 8 and 10 cumulative applications of DBC, hepatocyte counting revealed a significant cell loss from the 8th to 10th applications. As single-cell necrosis was first observed in the group that received 8 applications of DBC, the differences observed between these 2 groups could be due to this form of necrosis. Moreover, in vitro experiments have also shown the induction of apoptosis and necrosis in HepG2 cells by 7H-DBC (O'Brien et al., 2000) . This passive cell death could also contribute to the cell loss observed after 12 applications. Although the apoptosis index was also higher at the periportal area in the last group, a significant decrease in the number of hepatocytes was observed in the centrilobular region. This fact could be due not only to cell death but also to proliferation of biliary epithelium which constitutes a high proportion of the liver section.
Vol
There is currently no information on changes in gene expression in liver during treatment with 7H-DBC in vivo, nevertheless O'Brien et al. (2000) showed the induction of p53 by DBC in vitro using a human hepatoma cell line. In the present study we have analyzed the expression of p53 and p53 responsive genes at the mRNA and protein levels. As expected, p53 mRNA levels remained constant in all groups; the p53 tumor suppressor is activated following DNA damage through posttranscriptional mechanisms that increases its stability (Kastan et al., 1991; Fritsche et al., 1993; Gottlieb and Oren, 1996) . Under our experimental conditions a slight p53 staining was detected in hepatocyte nuclei of liver from treated mice although the intensity of this staining was much stronger in the 12 applications group. In some studies where the neoplastic process has been investigated, immunohistochemical detection of p53 proteins has been considered to be synonymous with p53 mutations (Bartek et al., 1990; Liu et al., 1994) . In addition, there is evidence that other DNA-adduct forming compounds, such as aflatoxin, can induce p53 mutations (Kobertz et al., 1997; Mace et al., 1997; Denissenko et al., 1998) . The antibody used in the present work for p53 immunohistochemical detection recognises both the mutant and the wild type proteins; the p53 nuclear staining observed in the early phases of the of 7H-DBC-induced toxic damage could be due to protein stabilization as a consequence either of a genotoxic stress or to a possible mutation. In addition to its nuclear localization, some hepatocytes showed an intense cytoplasmic p53 staining. Cytoplasmic sequestered wild-type p53 has been considered as a defect in p53 nuclear retention resulting from either the inhibition of the entry into the nucleus (Moll et al., 1996) or from its hyperactive export (Stommel et al., 1999) , and it may be a mechanism of p53 dysfunction in some tumour cells (Shaulsky et al., 1991; Ryan et al., 1994) .
Although the accumulation of p53 protein in both hepatocytes and mesenchymal cells has been described during early stages of rodent hepatocarcinogenesis (Lim, 2002) , in the present work, p53 was detected in macrophages from liver of control and treated animals. Because of their topological localization within the liver sinusoids, macrophages represent the first line of defence and the p53 response could be a physiological mechanism for elimination of damage cells. Further analysis with a more sensitive immunohistochemical protocol followed by quantification of positive stained mesenchymal cells could determine if the staining observed in this work in treated animals could be related to 7H-DBC toxicity. The induction of p53 by hepatocarcinogens which form DNA-adducts has been described in rat liver (van Gijssel et al., 1997) and in other models (Binkova et al., 2000; Carlisle et al., 2000) .
The action of Bax and Fas downstream of the induction of p53 by DNA damaging agents, including those which form DNA adducts, has also been reported (Vogelstein and Kinzler, 1992; Miyashita et al., 1994; Mitry et al., 1997; Muller et al., 1997; Owen-Schaub et al., 1995; Yoshizawa et al., 1999) . In this work we have observed a significant increase of Bax mRNA as early as the 8th application of 7H-DBC. This result was correlated with the immunohistochemical detection of Bax protein. No differences were observed between these groups that received 8 and 10 applications of 7H-DBC, neither at the transcript nor at the protein level. This result correlates with the absence of differences in the apoptosis index between this 2 groups, as death by necrosis does not need the expression of genes, and this fact could confirm our hypothesis that the differences in cell loss observed between 8 and 10 applications are due to necrosis rather than to apoptosis. Although the Bax transcripts detected at the 12th application were similar to those observed in the groups that received lower doses, an accumulation of Bax protein was detected by immunohistochemistry. Conversely, a slight increase of Fas staining was observed in treated animals although it was not clearly different in the different treated groups with the exception of the one receiving the highest cumulative dose. Significant differences in Fas mRNA were not observed although a slight increase was noticeable. These results could indicate that Bax is much more involved than Fas in the apoptosis induced by the genotoxic compound 7H-DBC. Both biomarkers are downstream effectors although they have been observed at times when p53 is hardly detected. Due to the short half-life of p53, the accumulation of these responsive genes could be more easily detected by immunohistochemical methods. These apoptosis genes are however not specific for genotoxic injuries where the detection of p53 is more pertinent.
In addition to the up-regulation of apoptotic genes (Bax and Fas), p53 has been shown to suppress antiapoptotic genes such as Bcl-2, thus altering the Bax/Bcl-2 ratio and shifting the balance towards apoptosis (Owen-Schaub et al., 1995) . We have not observed this down-regulation in our study. On the contrary, the up-regulation of Bcl-2 transcripts was detected in the groups of mice which received 8 or more cumulative applications of 7H-DBC. In normal liver and in liver with hepatic lesions showing ductular proliferation, Bcl-2 is expressed by bile ductules and small bile duct epithelium but not by hepatocytes (Charlotte et al., 1994) . Immunohistochemical studies have documented Bcl-2 expression in most human cholangiocarcinomas (Charlotte et al., 1994; Patel and Gores, 1995) and its altered expression seems to render the cholangiocarcinoma cells resistant to apoptosis (Harnois et al., 1997) . The up-regulation of Bcl-2 observed in the present work after 8 applications of 7H-DBC could be related to the bile duct proliferation and lymphocyte infiltration observed in treated animals, and this result is also in accordance with the DNA synthesis response observed in that group (Dorchies et al., 2001) . As no conclusive results were obtained when different antibodies were used to determine the physical localization of the Bcl-2 expression (data not shown), further analysis will be necessary to confirm this hypothesis.
The expression of TGF-β1 observed in control animals corresponds to the description in normal liver tissue where it is mainly produced by nonparenchymal cells. Moreover, this cytokine is also expressed in hepatocytes undergoing apoptosis (Oberhammer et al., 1992) . In our study apoptotic forms of hepatocytes showed positive immunostaining for TGF-β1 in liver from mice treated with 6, 8, or 10 applications of 7H-DBC. With respect to the up-regulation of TGF-β1 in hepatocytes observed in the 12 applications group, similar results can be found in the literature following regenerative liver growth, inflammatory response to tissue injury and the presence of hepatic fibrosis and hepatocarcinomas (Czaja et al., 1989; Fausto et al., 1990; Bedossa et al., 1995) . The overexpression of this cytokine in our study is similar to the one observed for Bax and Fas in the group that received the highest cumulative dose of 7H-DBC. Although TGF-β1 may play a dual role in hepatocytes by means of growth inhibition or enhancing tumor progression, the toxicity observed in these animals could indicate that the upregulation of this biomarker under our experimental conditions could be linked to apoptosis more than to carcinogenesis.
In summary, we have observed the early activation of the p53 apoptosis pathway in hepatocytes through the overexpression of Bax at low number of 7H-DBC applications. This phenomenon was confirmed by the nuclear localization of p53, which suggests genotoxic damage. Overexpression of these proteins was observed in hepatocytes but not in other liver cells, showing that the parenchymal cells may be more sensitive to the genotoxic damage induced by 7H-DBC, perhaps as a consequence of the metabolism of this compound. As a late event of the apoptosis process we have also observed the overexpression of the cytokine TGF-β1. This work contributes to the knowledge of the molecular mechanisms involved in the hepatotoxicity of 7H-DBC in mouse liver by means of the analysis of biomarker expression at the transcript and protein levels.
